254 related articles for article (PubMed ID: 24786143)
21. On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).
Khera AV; Qamar A; Murphy SA; Cannon CP; Sabatine MS; Rader DJ
Am J Cardiol; 2015 Sep; 116(5):694-8. PubMed ID: 26119654
[TBL] [Abstract][Full Text] [Related]
22. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Hoffman KB; Kraus C; Dimbil M; Golomb BA
PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
[TBL] [Abstract][Full Text] [Related]
23. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
[TBL] [Abstract][Full Text] [Related]
24. Comparison of statins in hypertriglyceridemia.
Stein EA; Lane M; Laskarzewski P
Am J Cardiol; 1998 Feb; 81(4A):66B-69B. PubMed ID: 9526817
[TBL] [Abstract][Full Text] [Related]
25. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
[TBL] [Abstract][Full Text] [Related]
26. Association of cholesteryl ester transfer protein mass with peripheral leukocyte count following statin therapy: a pilot study.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2012 Oct; 12(5):349-54. PubMed ID: 22900989
[TBL] [Abstract][Full Text] [Related]
27. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
[TBL] [Abstract][Full Text] [Related]
28. HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.
Lewicki M; Ng I; Schneider AG
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010480. PubMed ID: 25758322
[TBL] [Abstract][Full Text] [Related]
29. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).
Deedwania P; Stone PH; Bairey Merz CN; Cosin-Aguilar J; Koylan N; Luo D; Ouyang P; Piotrowicz R; Schenck-Gustafsson K; Sellier P; Stein JH; Thompson PL; Tzivoni D
Circulation; 2007 Feb; 115(6):700-7. PubMed ID: 17283260
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of short-term high versus low doses of atorvastatin preventing contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention.
Wu H; Li D; Fang M; Han H; Wang H
J Clin Pharmacol; 2015 Feb; 55(2):123-31. PubMed ID: 25310898
[TBL] [Abstract][Full Text] [Related]
31. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Rouleau J
Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
[TBL] [Abstract][Full Text] [Related]
32. [Statin therapy in patients with acute coronary syndrome. "Prove-it" study].
von Schacky C
Internist (Berl); 2004 Dec; 45(12):1437-9. PubMed ID: 15448925
[No Abstract] [Full Text] [Related]
33. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Saw J; Steinhubl SR; Berger PB; Kereiakes DJ; Serebruany VL; Brennan D; Topol EJ;
Circulation; 2003 Aug; 108(8):921-4. PubMed ID: 12925453
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
35. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Taylor AJ; Kent SM; Flaherty PJ; Coyle LC; Markwood TT; Vernalis MN
Circulation; 2002 Oct; 106(16):2055-60. PubMed ID: 12379573
[TBL] [Abstract][Full Text] [Related]
36. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.
McLean DS; Ravid S; Blazing M; Gersh B; Shui A; Cannon CP
Am Heart J; 2008 Feb; 155(2):298-302. PubMed ID: 18215600
[TBL] [Abstract][Full Text] [Related]
37. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
[TBL] [Abstract][Full Text] [Related]
38. [Association between high sensitivity C-reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin].
Su JZ; Xue Y; Cai WQ; Huang QY; Chai DJ; Chen GL; Wang FB; Chen XP; Zhang DS
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Sep; 39(9):807-11. PubMed ID: 22321227
[TBL] [Abstract][Full Text] [Related]
39. Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.
Eisen A; Cannon CP; Braunwald E; Steen DL; Zhou J; Goodrich EL; Im K; Dalby AJ; Spinar J; Daga S; Lukas MA; O'Donoghue ML
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28077384
[TBL] [Abstract][Full Text] [Related]
40. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.
Scirica BM; Morrow DA; Cannon CP; Ray KK; Sabatine MS; Jarolim P; Shui A; McCabe CH; Braunwald E;
J Am Coll Cardiol; 2006 Jun; 47(11):2326-31. PubMed ID: 16750703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]